{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:13:09Z","timestamp":1778926389998,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.breast.2026.104780","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:56:28Z","timestamp":1774929388000},"page":"104780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world progression-free survival 2 (PFS2) and tumor response of CDK4\/6 inhibitors plus an aromatase inhibitor in patients with HR+\/HER2\u2212 metastatic breast cancer in US routine clinical practice"],"prefix":"10.1016","volume":"87","author":[{"given":"Hope S.","family":"Rugo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel M.","family":"Layman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"McRoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Estevez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Thill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104780_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2026.104780_bib5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104780_bib8","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1016\/j.annonc.2023.09.624","article-title":"448P real-world experience with CDK4\/6 inhibitors for HR+\/HER2-metastatic breast cancer (MBC)","volume":"34","author":"Abdallah","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib9","doi-asserted-by":"crossref","first-page":"1203684","DOI":"10.3389\/fonc.2023.1203684","article-title":"The effectiveness and safety of palbociclib and ribociclib in stage IV HR+\/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study","volume":"13","author":"Al-Ziftawi","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib10","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1177\/10781552231163121","article-title":"CDK4\/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset","volume":"29","author":"Buller","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.breast.2026.104780_bib11","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.3390\/ijms24108488","article-title":"Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer","volume":"24","author":"Cejuela","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104780_bib12","first-page":"100818","article-title":"CDK4\/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: a real-world and propensity score-adjusted comparison","volume":"40","author":"Coutinho-Almeida","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.breast.2026.104780_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s44276-024-00070-w","article-title":"Real-world effectiveness of CDK 4\/6 inhibitors in estrogen-positive metastatic breast cancer","volume":"2","author":"Gehrchen","year":"2024","journal-title":"BJC Reports"},{"key":"10.1016\/j.breast.2026.104780_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/fon-2022-1287","article-title":"Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"19","author":"Kahraman","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib15","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3390\/diagnostics13111938","article-title":"Real-world outcomes of CDK4\/6 inhibitors treatment in metastatic breast cancer in Romania","volume":"13","author":"Miron","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.breast.2026.104780_bib16","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.3390\/cancers15215164","article-title":"Clinical Impact of CDK4\/6 Inhibitors in De Novo or PR\u2212 or Very Elderly Post-Menopausal ER+\/HER2\u2212 Advanced Breast Cancers","volume":"15","author":"Tang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2026.104780_bib17","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/ijc.35296","article-title":"Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive\/HER2-negative metastatic breast cancer with real-world data from the OPAL registry","volume":"156","author":"Thill","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104780_bib18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2024.42.16_suppl.1014","article-title":"Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+\/HER2- aBC: results of the multicenter, real-world, Italian study PALMARES-2","volume":"42","author":"Vernieri","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib19","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1186\/s12885-024-12765-x","article-title":"Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR +\/HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand","volume":"24","author":"Dajsakdipon","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104780_bib20","doi-asserted-by":"crossref","first-page":"104103","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104780_bib21","series-title":"Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer in US routine clinical practice","author":"Rugo","year":"2025"},{"key":"10.1016\/j.breast.2026.104780_bib22","article-title":"Approach to machine learning for extraction of real-world data variables from electronic health records","volume":"14:1180962","author":"Adamson","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.breast.2026.104780_bib23","series-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"2020"},{"key":"10.1016\/j.breast.2026.104780_bib24","series-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2020"},{"key":"10.1016\/j.breast.2026.104780_bib25","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/cancers15061853","article-title":"Replication of real-world evidence in oncology using electronic health record data extracted by machine learning","volume":"15","author":"Benedum","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2026.104780_bib26","article-title":"Raising the bar for real-world data in oncology: approaches to quality across multiple dimensions","volume":"8","author":"Castellanos","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.breast.2026.104780_bib27","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3390\/cancers14133063","article-title":"Considerations for the use of machine learning extracted real-world data to support evidence generation: a research-centric evaluation framework","volume":"14","author":"Estevez","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2026.104780_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ijc.34748","article-title":"Real\u2010world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron database","volume":"154","author":"Rugo","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104780_bib29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11523-021-00826-1","article-title":"Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice","volume":"16","author":"Brufsky","year":"2021","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib30","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s12325-021-01659-0","article-title":"Characterization of a real-world response variable and comparison with RECIST-based response rates from clinical trials in advanced NSCLC","volume":"38","author":"Ma","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.breast.2026.104780_bib31","article-title":"Ensuring reliability of curated EHR-derived data: the validation of accuracy for LLM\/ML-Extracted information and data (VALID) framework","author":"Estevez","year":"2025","journal-title":"arXiv preprint arXiv:2506.08231."},{"key":"10.1016\/j.breast.2026.104780_bib32","series-title":"Concordance of response-based clinical trial and machine learning\u2013generated real-world end points","author":"Zhang","year":"2025"},{"key":"10.1016\/j.breast.2026.104780_bib33","article-title":"MSR79 evaluation of real-world response rate in clinical trial-aligned cohorts of patients with lung, colon, and breast cancer using machine learning","volume":"27","author":"Zhang","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2026.104780_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2025.04.1293","article-title":"MSR142 performance assessment and validation of real-world response data generated using a deep learning-based natural language processing model across multiple solid tumors","volume":"28","author":"Magee","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2026.104780_bib35","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3389\/fonc.2020.01349","article-title":"Systematic review and meta-analysis of correlation of progression-free Survival-2 and overall survival in solid tumors","volume":"10","author":"Chowdhury","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib36","series-title":"Guideline on the evaluation of anticancer medicinal products in man","year":"2017"},{"key":"10.1016\/j.breast.2026.104780_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100332","article-title":"Systematic review and meta-analysis of post-progression outcomes in ER+\/HER2- metastatic breast cancer after CDK4\/6 inhibitors within randomized clinical trials","volume":"6","author":"Munzone","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104780_bib38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in Pre- and perimenopausal patients with HR+\/HER2\u2212 advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104780_bib39","first-page":"113","article-title":"326P - MONARCH 3: updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+","volume":"30","author":"Martin","year":"2019","journal-title":"HER2- advanced breast cancer (ABC)"},{"key":"10.1016\/j.breast.2026.104780_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2\u2212 advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104780_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-Negative breast cancer that progressed on endocrine Therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib42","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104780_bib43","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer","volume":"123","author":"Cooper","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104780_bib44","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/curroncol30020143","article-title":"Harnessing real-world evidence to advance cancer research","volume":"30","author":"Tang","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib45","article-title":"Evaluation of real-world tumor response derived from electronic health record data sources: a feasibility analysis in patients with metastatic non-small cell lung cancer treated with chemotherapy","volume":"8","author":"McKelvey","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.breast.2026.104780_bib46","first-page":"100683","article-title":"Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4\/6 inhibitors: results from a reference center in Brazil","volume":"35","author":"Queiroz","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.breast.2026.104780_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241302018","article-title":"Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+\/HER2\u2212metastatic breast cancer patients: a multicenter study (YOUNGBC-28)","volume":"16","author":"Chen","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2026.104780_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/865101","article-title":"Which metrics are appropriate to describe the value of new cancer therapies?","volume":"2015","author":"Johnson","year":"2015","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.breast.2026.104780_bib49","doi-asserted-by":"crossref","first-page":"8457","DOI":"10.2147\/CMAR.S328058","article-title":"The impasse on overall survival in oncology reimbursement decision-making: how can we resolve this?","volume":"13","author":"Lux","year":"2021","journal-title":"Cancer Manag Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:57:19Z","timestamp":1778925439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["S0960977626000901"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104780","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world progression-free survival 2 (PFS2) and tumor response of CDK4\/6 inhibitors plus an aromatase inhibitor in patients with HR+\/HER2\u2212 metastatic breast cancer in US routine clinical practice","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104780"}}